Intermatic smart timer4/6/2023 “Our results may aid shared decision-making between clinicians and patients seeking to understand the relative merits of different treatment options for moderate-to-severe atopic dermatitis,” the team wrote.Ībout Heads Up 1. Investigators observed little or no difference between upadacitinib, 15 mg daily, and dupilumab (MD, 0.2 95% CrI, −1.9 to 2.2 high certainty). Methods Data were pooled for patients with RA who received ≥1 tofacitinib dose. We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term extension studies in adult patients with RA. Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The trial enrolled adults with moderate to severe AD from 129 clinical centers around the world.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |